Cian Healthcare Limited
BSE: CHCL · Pharmaceuticals · sector
₹30.96BSE close 2026-10-26
Key numbers
Market cap₹77 cr
Price₹30.96
52w high / low₹31 / ₹5
P/E3.3xSector median 27.9x
P/B–Sector median 2.9x
Book value₹-6.6
Dividend yield–Sector median 0.48%
ROE–Sector median 11.7%
ROCE–Sector median 12.3%
OPM-71.5%Sector median 14.0%
Debt / equity–Sector median 0.16x
EV/EBITDA–Sector median 18.6x
Interest cover-107.1x
Current ratio0.78x
Sales growth 3y-25.2%Sector median +9.6%
Profit growth 3y–Sector median +13.3%
PEG0.02x
Last 12 months to Mar 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Operating profit covered interest -107.1x in the last 12 months.
- Net loss in 3 of the last 3 quarters.
- No dividend in the last 5 financial years.
- Price ₹30.96 on 2026-10-26: 0.0% from the 52-week high, +555.9% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹30.96 · low ₹7.87
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|
| Revenue | 12 | 11 | 17 |
| EBITDA | -5 | -4 | -16 |
| OPM % | -46.1% | -34.5% | -96.1% |
| Other income | 0 | 1 | 1 |
| Net profit | -8 | -5 | -18 |
| EPS (₹) | 3.09 | 2.13 | 7.19 |
Consolidated figures where filed. Latest quarter Mar 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 64 | 68 | 59 | 31 | 28 | 28 |
| EBITDA | 5 | 8 | 7 | -19 | -20 | -20 |
| Net profit | -2 | 1 | 0 | -26 | -23 | -23 |
| EPS (₹) | -0.96 | 0.43 | 0.16 | 10.39 | 9.32 | 9.32 |
| Revenue growth | +5.4% | -13.0% | -47.6% | -8.1% | – | |
| Profit growth | – | -63.9% | -6,761.5% | – | – | |
| Dividend / share (₹) | – | – | – | – | – |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | -25.2% | – | – |
| Net profit | – | – | – |
| EPS | +178.8% | – | – |
| Share price | – | +154.4% (2y) | +379.4% |
Balance sheet
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Shareholders' equity | 7 | -16 |
| Cash & equivalents | 18 | 1 |
| Total assets | 156 | 62 |
| Fixed assets | 35 | 32 |
| Investments | 5 | 0 |
| Inventory | 26 | 5 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Cash from operations | 21 | 21 |
| Cash from investing | -0 | 13 |
| Cash from financing | -4 | -50 |
| Capex | 0 | 8 |
| Free cash flow | 20 | 12 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY25 | FY26 |
|---|---|---|
| ROE % | -352.9% | 141.5% |
| ROCE % | -313.5% | 139.5% |
| Inventory days | 420 | 82 |
| Working capital days | -517 | -81 |
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| CHCL | ₹77 cr | 3.3x | – | – | – | -71.5% | -25.2% | – |
Documents
Links go to the original files on the exchange website.
About the company
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | CHCL |
| BSE code | 542678 |
| ISIN | INE05BN01027 |
| Face value | ₹10.0 |
| Incorporated | – |
| Website | – |
| Plants (India / abroad) | – |
Data built 2026-10-24 from BSE company filings (inline XBRL: Integrated Filing - Finance) + BSE results summary for earlier years; price = BSE close 2026-10-26.